ANSWER: B

Rationale:

The correct answer is B. Isosorbide mononitrate (ISMN) is the active metabolite of isosorbide dinitrate (ISDN). Because ISMN is already in its pharmacologically active mononitrate form, it does not require ALDH2-mediated denitration — it releases nitric oxide (NO) via non-ALDH2 pathways and is considered partially pre-activated. By contrast, nitroglycerin (GTN) and ISDN both require ALDH2 for bioactivation: ALDH2 cleaves nitrate groups, generating inorganic nitrite that is then reduced to NO. This distinction is clinically important for two reasons: ALDH2 is the enzyme inactivated during nitrate tolerance (explaining why ISMN may have modestly lower tolerance potential), and ALDH2 is inhibited by disulfiram, which can impair GTN and ISDN bioactivation in patients on alcohol-sensitizing therapy.

• Option A: Option A is incorrect: nitroglycerin requires ALDH2 for bioactivation; water solubility does not confer enzymatic independence, and GTN is actually a lipophilic molecule that readily crosses membranes.
• Option C: Option C is incorrect: ISDN requires ALDH2-mediated denitration, not simultaneous plasma esterase hydrolysis; ISDN is one of the two primary ALDH2-dependent nitrates.
• Option D: Option D is incorrect: the route of administration (transdermal) does not alter the enzymatic requirement for bioactivation; once absorbed into the systemic circulation, transdermal GTN still requires ALDH2 in vascular smooth muscle mitochondria.
• Option E: Option E is incorrect: there is no established cytochrome P450-dependent alternative pathway that substitutes for ALDH2 when it is saturated; ALDH2 saturation is precisely the mechanism of tolerance, not a trigger for pathway switching.

ANSWER: D

Rationale:

The correct answer is D. The standard protocol for sublingual nitroglycerin use in acute angina is: one tablet (or spray) under the tongue at the onset of symptoms; the patient should sit or lie down to minimize hypotension risk; if no relief after 5 minutes, a second tablet may be taken; if still no relief after another 5 minutes, a third tablet may be taken; if chest pain is not relieved after three doses over approximately 15 minutes, emergency services must be activated immediately, as persistent pain unresponsive to three doses of nitroglycerin should be treated as a possible acute coronary syndrome until proven otherwise. SL-NTG has an onset of 1–3 minutes and peak effect at approximately 5 minutes — the 5-minute repeat interval is calibrated to this pharmacokinetic profile.

• Option A: Option A is incorrect: a 30-minute interval before repeating and a 60-minute window before calling EMS are dangerously prolonged; an evolving myocardial infarction can cause irreversible damage within this time frame.
• Option B: Option B is incorrect: repeating every 10 minutes for up to 5 doses extends the period without emergency evaluation far beyond safe limits; a 60-minute delay before activating EMS is not acceptable in the setting of persistent chest pain.
• Option C: Option C is incorrect: the instruction not to repeat dosing for 20 minutes conflicts with the pharmacokinetic profile of SL-NTG (onset 1–3 minutes, duration 20–30 minutes) and unnecessarily withholds potential relief; lying flat is appropriate but the dosing restriction is incorrect.
• Option E: Option E is incorrect: SL-NTG must not be swallowed — oral nitroglycerin undergoes approximately 99% first-pass hepatic extraction and has virtually no systemic bioavailability; swallowing the tablet negates its pharmacological effect.

ANSWER: A

Rationale:

The correct answer is A. The transdermal nitroglycerin patch must be applied in the morning and removed in the evening — the standard instruction is "wear 12 hours, remove 12 hours" or "12 on/12 off." This creates a nitrate-free interval (NFI) of approximately 10–12 hours overnight, during which mitochondrial aldehyde dehydrogenase 2 (ALDH2) is regenerated, neurohormonal pseudotolerance resolves, and vascular sensitivity to nitrates is restored. Failure to remove the patch causes continuous nitrate exposure, and tolerance develops within 24–48 hours — one of the most common errors in outpatient nitrate prescribing. Patients must be explicitly counseled that removing the patch at bedtime is deliberate and protective, not a gap in therapy. During the overnight nitrate-free interval, non-nitrate anti-ischemic coverage with a beta-blocker or non-dihydropyridine calcium channel blocker (CCB) should be maintained.

• Option B: Option B is incorrect: a weekly replacement cycle provides no daily nitrate-free interval and guarantees continuous nitrate exposure — tolerance would develop within the first 24–48 hours of wear regardless of how frequently the patch is replaced.
• Option C: Option C is incorrect: applying the patch at bedtime and removing it in the morning reverses the anti-ischemic coverage window; most exertional angina occurs during waking hours, and the early morning — the highest-risk circadian period — would be covered by only the tail of the patch's effect as it is being removed.
• Option D: Option D is incorrect: dose escalation is not a valid strategy for managing tolerance; tolerance is a pharmacodynamic phenomenon driven by ALDH2 inactivation and neurohormonal activation, not by insufficient drug concentration, and increasing the dose does not restore ALDH2 function.
• Option E: Option E is incorrect: transdermal nitroglycerin produces sustained systemic plasma concentrations sufficient to activate ALDH2 and generate the reactive oxygen species that inactivate it; the route of administration does not protect against tolerance, which is why the nitrate-free interval is mandatory even for the patch.

ANSWER: C

Rationale:

The correct answer is C. Nitric oxide (NO) released from organic nitrates diffuses freely into vascular smooth muscle cells and binds to the heme iron center of soluble guanylyl cyclase (sGC), the receptor enzyme for NO. Activated sGC converts GTP to cyclic GMP (cGMP). Elevated cGMP activates protein kinase G (PKG), which phosphorylates myosin light chain kinase (MLCK), reducing its catalytic activity. Since MLCK is the enzyme responsible for phosphorylating myosin light chains — the obligatory step for actin-myosin cross-bridge cycling and smooth muscle contraction — reduced MLCK activity decreases myosin light chain phosphorylation and produces smooth muscle relaxation and vasodilation. This NO-sGC-cGMP-PKG-MLCK cascade is the core mechanism shared by organic nitrates and endogenous endothelial NO.

• Option A: Option A is incorrect: NO does not act through beta-2 adrenoceptors or adenylyl cyclase; the cAMP-PKA pathway is the mechanism of beta-2 agonists and prostacyclin, not of NO.
• Option B: Option B is incorrect: while BKCa (large-conductance calcium-activated potassium) channels are activated downstream of PKG, NO does not directly open KATP channels independent of the sGC-cGMP second messenger cascade; the described pathway omits the essential sGC-cGMP-PKG intermediate.
• Option D: Option D is incorrect: NO does not inhibit PDE5; PDE5 inhibitors (sildenafil, tadalafil) are separate pharmacological agents that prevent cGMP degradation, acting downstream of the NO-sGC step. The combination of nitrates and PDE5 inhibitors is absolutely contraindicated because of additive cGMP accumulation.
• Option E: Option E is incorrect: the PLC-IP3-calcium-MLCK pathway describes a contractile signaling cascade (e.g., alpha-1 adrenergic stimulation), not a relaxation pathway; NO acts in precisely the opposite direction on smooth muscle calcium-dependent contractile mechanisms.

ANSWER: E

Rationale:

The correct answer is E. Tadalafil has a plasma half-life of approximately 17.5 hours — substantially longer than sildenafil (approximately 4 hours) and vardenafil (approximately 4–5 hours). Because the risk of dangerous cyclic GMP (cGMP) potentiation persists as long as meaningful PDE5 inhibitor plasma concentrations exist, the absolute contraindication to all nitrate formulations is extended to 48 hours after the last tadalafil dose. At 30 hours post-ingestion, tadalafil plasma concentrations remain clinically significant, and the interaction risk is not resolved. The mechanism: nitrates generate NO which activates soluble guanylyl cyclase (sGC) to increase cGMP; PDE5 inhibitors prevent cGMP degradation; the combination produces dramatically amplified and prolonged vasodilation causing severe, potentially fatal hypotension. The correct emergency management in this patient is to withhold all nitrates and use alternative analgesia — intravenous morphine, supplemental oxygen, and isotonic IV fluids — while arranging urgent evaluation.

• Option A: Option A is incorrect: the 24-hour window applies to sildenafil and vardenafil, not to tadalafil; applying the shorter window to tadalafil is a clinically dangerous error that ignores tadalafil's prolonged pharmacokinetic profile.
• Option B: Option B is incorrect: there is no evidence-based half-dose protocol that renders the combination safe within the contraindication window; the interaction is an absolute contraindication, not a dose-dependent relative risk.
• Option C: Option C is incorrect: the absolute contraindication applies to all nitrate formulations regardless of route or duration of action; the pharmacodynamic interaction occurs at the vascular smooth muscle level and is not mitigated by a short nitrate duration.
• Option D: Option D is incorrect: the PDE5 inhibitor-nitrate interaction is an absolute contraindication, not a relative one; no blood pressure threshold makes the combination safe within the contraindication window.

ANSWER: B

Rationale:

The correct answer is B. Isosorbide mononitrate extended-release (ISMN-ER) has three properties that make it the preferred oral nitrate for most outpatients with stable angina. First, once-daily dosing produces the best adherence profile among oral nitrate formulations — twice-daily regimens with eccentric timing (required for ISMN-IR and ISDN) are prone to dosing errors. Second, ISMN has approximately 100% oral bioavailability because, as the active mononitrate form, it does not undergo significant first-pass hepatic metabolism; plasma concentrations are predictable and consistent between patients regardless of hepatic metabolic capacity. Third, a single dose taken at 7:00 AM provides anti-ischemic coverage during waking hours and the extended-release profile wanes by approximately 7:00 PM, automatically generating an overnight nitrate-free interval of approximately 12 hours without any additional patient action.

• Option A: Option A is incorrect: ISMN-ER has an onset of approximately 30–60 minutes and is entirely unsuitable for acute angina relief; SL-NTG (onset 1–3 minutes) is the agent for acute symptom management.
• Option C: Option C is incorrect: ISMN-ER absolutely requires a nitrate-free interval — the once-daily morning dosing strategy is specifically designed to provide this interval. Continuous extended-release delivery without a gap would cause tolerance within 24–48 hours, as demonstrated with continuous-wear NTG patches.
• Option D: Option D is incorrect: ISMN is not a prodrug requiring hepatic conversion; it is already the active mononitrate form and does not generate a dinitrate metabolite; it is ISDN that is metabolized to active mononitrate forms, not the reverse.
• Option E: Option E is incorrect: no oral nitrate formulation, including ISMN-ER, has demonstrated mortality or MI reduction in stable coronary artery disease; long-acting nitrates are anti-anginal and anti-ischemic agents only and do not modify the underlying atherosclerotic disease process.

ANSWER: D

Rationale:

The correct answer is D. ST elevation in lead V4R (a right-sided precordial lead) is the diagnostic finding of right ventricular (RV) infarction, which complicates approximately 30–50% of inferior wall STEMIs due to proximal right coronary artery occlusion involving the RV marginal branches. The infarcted right ventricle cannot generate normal contractile force and becomes critically dependent on adequate preload — venous return and right ventricular filling pressure — to maintain output across the pulmonary vasculature and into the left heart. Nitroglycerin's primary hemodynamic action is venodilation with reduction in venous return. In RV infarction, this preload reduction removes the filling reserve on which right ventricular output depends, causing RV output to collapse with consequent loss of left ventricular filling and precipitous systemic hypotension. The correct management is the opposite of vasodilation: isotonic saline (0.9% NaCl) volume loading to increase right ventricular preload and restore RV output. Nitroglycerin must be withheld entirely.

• Option A: Option A is incorrect: inferior STEMI involves the right coronary artery territory, not the left anterior descending artery; coronary steal is not the mechanism of contraindication, and norepinephrine is not the first-line treatment for RV infarction hypotension.
• Option B: Option B is incorrect: while SBP below 90 mmHg is a general caution for nitrate use, the specific absolute contraindication here is RV infarction physiology — the mechanism is preload dependence, not simply low blood pressure. Volume loading, not vasopressors, is the correct initial approach.
• Option C: Option C is incorrect: IV-NTG is recommended (ACC/AHA Class I) for persistent ischemic symptoms and pulmonary congestion in most STEMI presentations; the contraindication is specific to confirmed or suspected RV infarction.
• Option E: Option E is incorrect: PDE5 inhibitor use is a separate contraindication requiring direct questioning, but is not diagnosed from hemodynamic findings alone, and calcium gluconate is not the antidote for the nitrate-PDE5 interaction.

ANSWER: A

Rationale:

The correct answer is A. Nitrate-induced headache is the most common adverse effect of organic nitrates, affecting approximately 30–60% of patients at initiation. The mechanism is nitric oxide (NO)-mediated vasodilation of cerebrovascular vessels, producing a throbbing, frontal headache that begins within minutes of drug administration. A critical and clinically actionable teaching point is that cephalic tolerance — tolerance of the headache response — develops faster than hemodynamic tolerance — tolerance of the vasodilatory anti-ischemic effect. Within 1–2 weeks of regular dosing, the headache diminishes substantially or resolves entirely in most patients, while meaningful anti-ischemic benefit is preserved. Management is acetaminophen for symptom relief during this initial period. Patients must be explicitly counseled that the headache is expected, not dangerous, and does not indicate drug toxicity or loss of efficacy; abrupt discontinuation of the nitrate due to headache is one of the most common causes of subtherapeutic nitrate use in clinical practice.

• Option B: Option B is incorrect: nitrate-induced headache reflects cerebrovascular vasodilation, not systemic hypotension causing cerebral hypoperfusion; a patient with significant nitrate-induced hypotension would present with dizziness, lightheadedness, or syncope rather than isolated frontal headache.
• Option C: Option C is incorrect: cephalic tolerance (headache resolution) and hemodynamic tolerance (loss of anti-ischemic effect) are distinct processes developing at different rates; headache resolution does not indicate loss of anti-ischemic efficacy, and discontinuation is not warranted at five days.
• Option D: Option D is incorrect: the headache is not caused by rebound hypertension during the nitrate-free interval; it is caused by NO-mediated cerebrovascular vasodilation immediately after dosing. Switching to a continuous patch without a removal interval would cause hemodynamic tolerance.
• Option E: Option E is incorrect: organic nitrates do not cause intracranial hypertension; the headache is vascular in mechanism and does not represent increased cerebrospinal fluid pressure or a neurosurgical emergency.

ANSWER: C

Rationale:

The correct answer is C. The primary molecular mechanism of organic nitrate tolerance is oxidative inactivation of mitochondrial aldehyde dehydrogenase 2 (ALDH2). During nitroglycerin (GTN) bioactivation, ALDH2 catalyzes the denitration of GTN to generate inorganic nitrite and subsequently nitric oxide (NO). This reaction generates reactive oxygen species as byproducts — specifically superoxide and peroxynitrite — that oxidatively damage and inactivate ALDH2 itself. The result is a self-limiting cycle: continuous nitrate administration generates the reactive species that destroy the very enzyme required for NO generation, progressively reducing the capacity to bioactivate GTN and produce the vasodilatory NO signal. This mechanism is specific to ALDH2-dependent nitrates (GTN and ISDN); it explains why the nitrate-free interval (NFI) is essential — the NFI allows ALDH2 regeneration and restoration of bioactivation capacity.

• Option A: Option A is incorrect: while sGC downregulation has been proposed as a contributing molecular adaptation in chronic NO exposure, it is not the established primary mechanism of acute nitrate tolerance; ALDH2 inactivation is the primary mechanism and is supported by the most direct experimental evidence.
• Option B: Option B is incorrect: PDE5 upregulation has been studied as a potential tolerance mechanism but is not the primary established mechanism; furthermore, PDE5 inhibition (which would counteract this) is absolutely contraindicated with nitrates.
• Option D: Option D is incorrect: NO receptor desensitization via heme site saturation is not an established mechanism of organic nitrate tolerance; sGC remains responsive to NO even during tolerance states, which is why the problem lies upstream at the bioactivation step.
• Option E: Option E is incorrect: competitive inhibition by endogenous acetaldehyde is not a recognized mechanism of nitrate tolerance; the oxidative damage to ALDH2 is covalent and irreversible within the tolerance timeframe, not a reversible competitive inhibition by a metabolic byproduct.

ANSWER: E

Rationale:

The correct answer is E. Nitroglycerin has high affinity for polyvinyl chloride (PVC), the material used in standard intravenous administration sets. The drug adsorbs onto the inner surface of PVC tubing, and a clinically significant fraction of the prescribed dose never reaches the patient — the extent of loss depends on NTG concentration, flow rate, and tubing length but can be substantial. Since IV-NTG is titrated to hemodynamic effect (target blood pressure, preload reduction, symptom relief), unreliable drug delivery from PVC adsorption makes accurate titration impossible and may result in either undertreated ischemia or unpredictable hemodynamic changes when tubing is changed. Non-PVC tubing — polyethylene or polyolefin sets — eliminates adsorption and ensures that the delivered dose corresponds to the prescribed infusion rate. This is a mandatory preparation step whenever IV-NTG is ordered.

• Option A: Option A is incorrect: while nitroglycerin has historically been prepared in glass bottles due to adsorption concerns with certain plastic containers, the primary well-established clinical concern with standard IV administration is PVC tubing adsorption, not plasticizer reactions causing vasculitis.
• Option B: Option B is incorrect: nitroglycerin does not precipitate into microparticles at clinical infusion rates; the drug remains in solution across the clinical dosing range and does not require in-line filtration for this reason.
• Option C: Option C is incorrect: nitroglycerin does not crystallize in IV tubing at room temperature; temperature-dependent crystallization is not an established clinical concern with IV-NTG preparations at standard infusion conditions.
• Option D: Option D is incorrect: while nitroglycerin solutions can degrade with prolonged light exposure, this is managed by using appropriate storage conditions for the prepared infusion bag; light-protected tubing is not the primary mandatory requirement, and the 50% one-hour degradation figure described is not accurate under clinical conditions.

ANSWER: B

Rationale:

The correct answer is B. Organic nitrates oxidize ferrous hemoglobin (Fe2+) to ferric methemoglobin (Fe3+). Methemoglobin cannot carry oxygen and causes a left shift of the oxyhemoglobin dissociation curve in remaining functional hemoglobin, impairing tissue oxygen delivery. The clinical presentation is cyanosis that does not improve with supplemental oxygen — because the lungs are adequately delivering oxygen but the hemoglobin cannot transport it. Pulse oximetry reads approximately 85% regardless of actual saturation, because the standard two-wavelength pulse oximeter cannot distinguish methemoglobin from oxyhemoglobin and defaults to this intermediate spurious value; co-oximetry using multiple wavelengths is required for accurate diagnosis and confirms elevated methemoglobin fraction. Methemoglobinemia is clinically significant at high-dose IV-NTG (greater than 5 mcg/kg/min for prolonged periods) or with concurrent oxidizing agents such as dapsone, benzocaine, or lidocaine. Treatment is methylene blue 1–2 mg/kg intravenously, which reduces methemoglobin back to functional hemoglobin via the NADPH-dependent methemoglobin reductase system.

• Option A: Option A is incorrect: carbon monoxide poisoning also causes a falsely elevated pulse oximetry reading — standard two-wavelength oximetry reads carboxyhemoglobin as oxyhemoglobin, producing a near-normal (not 85%) reading; the clinical context of high-dose IV-NTG infusion points to methemoglobinemia, not CO poisoning.
• Option C: Option C is incorrect: pulmonary embolism causes hypoxemia via ventilation-perfusion mismatch with normal hemoglobin function; pulse oximetry would accurately reflect low oxygen saturation rather than produce the characteristic 85% spurious reading seen with methemoglobinemia.
• Option D: Option D is incorrect: cyanide toxicity is a complication of sodium nitroprusside metabolism, not organic nitrate metabolism; cyanide toxicity presents with lactic acidosis, altered consciousness, and cardiovascular collapse, not isolated hemoglobin oxidation.
• Option E: Option E is incorrect: organic nitrates do not cause bronchospasm; they produce smooth muscle relaxation, and bronchodilation is a minor secondary effect; the presentation described is not consistent with an airway mechanism.

ANSWER: D

Rationale:

The correct answer is D. Long-acting organic nitrates — isosorbide mononitrate, isosorbide dinitrate, and transdermal nitroglycerin — are effective anti-anginal and anti-ischemic agents. They reduce the frequency of anginal episodes, increase exercise duration before ischemic threshold, and improve quality of life and functional capacity. However, no randomized controlled trial has demonstrated that long-acting nitrates reduce mortality, myocardial infarction, or other hard cardiovascular endpoints in stable coronary artery disease. Their mechanism — venodilation reducing preload and wall stress, epicardial coronary vasodilation, and modest platelet inhibition — does not translate to the plaque-stabilizing, anti-thrombotic, or mortality-reducing benefits demonstrated by beta-blockers (post-MI), ACE inhibitors (reduced EF or diabetes), statins, and antiplatelet agents. Long-acting nitrates must always be prescribed alongside evidence-based disease-modifying therapies. This distinction is essential for informed patient counseling and accurate pharmacological classification of the drug's role in management.

• Option A: Option A is incorrect: while NO has anti-inflammatory properties in vitro, long-acting nitrate therapy has not been shown to stabilize coronary plaques or reduce MI risk through any mechanism in clinical trial evidence.
• Option B: Option B is incorrect: no outcome trial has demonstrated mortality reduction with long-acting nitrates in stable CAD; the comparison to beta-blockers in outcome benefit is not supported by evidence.
• Option C: Option C is incorrect: long-acting nitrates have not been shown to reduce MI risk even in vasospastic angina; calcium channel blockers, not nitrates, are the primary preventive agents for vasospasm-related events.
• Option E: Option E is incorrect: organic nitrates have no established anti-arrhythmic mechanism and have not been shown to reduce sudden cardiac death in stable CAD; the NO-mediated cardiac action potential stabilization described is not a recognized clinical pharmacological effect.

ANSWER: A

Rationale:

The correct answer is A. The most important safety precaution with sublingual nitroglycerin (SL-NTG) is that the patient should sit or lie down before administration. Nitroglycerin's primary hemodynamic action is venodilation with reduction in venous return, causing a fall in blood pressure. In a standing patient — particularly one who is elderly, hypovolemic, has autonomic dysfunction, or is taking other vasodilators or alcohol — this blood pressure reduction can cause orthostatic hypotension and syncope. The risk is greatest with the first dose of any new nitrate formulation and diminishes somewhat with subsequent doses as the patient becomes familiar with the drug's hemodynamic effect. Specific high-risk scenarios include: first SL-NTG use, elderly patients with impaired baroreceptor reflexes, concurrent dihydropyridine calcium channel blocker or alpha-blocker use, dehydration, and recent alcohol ingestion. Instructing the patient to be seated or supine before use is a simple and effective safety measure.

• Option B: Option B is incorrect: swallowing water after the tablet dissolves is unnecessary and potentially counterproductive — any remaining undissolved tablet fragment swallowed with water would undergo extensive first-pass hepatic metabolism; the instruction also adds no safety benefit.
• Option C: Option C is incorrect: 30 minutes of strict recumbency is unnecessarily restrictive and impractical — the hemodynamic effect of SL-NTG peaks at approximately 5 minutes and largely dissipates within 20–30 minutes; the patient should remain seated until symptoms resolve and they feel stable, not for a fixed 30-minute period.
• Option D: Option D is incorrect: standing is precisely the position to avoid; adequate sublingual absorption occurs regardless of body position because it depends on buccal mucosal blood flow, which is not significantly reduced by sitting or lying flat.
• Option E: Option E is incorrect: food does not meaningfully alter sublingual nitroglycerin bioavailability through mucosal pH changes; the sublingual route bypasses gastrointestinal factors entirely, and no meal-timing restriction is part of standard SL-NTG prescribing instructions.

ANSWER: C

Rationale:

The correct answer is C. In hypertrophic obstructive cardiomyopathy (HOCM), dynamic obstruction of the left ventricular outflow tract (LVOT) is caused by systolic anterior motion of the anterior mitral leaflet toward the hypertrophied interventricular septum. The severity of LVOT obstruction is directly and critically dependent on left ventricular (LV) volume: a smaller LV cavity during systole brings the anterior mitral leaflet closer to the septum, dramatically worsening obstruction and reducing forward cardiac output. Any intervention that reduces LV filling — including nitroglycerin-induced venodilation with reduced venous return, dehydration, the Valsalva maneuver, or standing — decreases LV volume and worsens obstruction, potentially causing syncope or hemodynamic collapse. Organic nitrates, whose primary hemodynamic action is venodilation with reduction in preload and LV end-diastolic volume, are therefore absolutely contraindicated in HOCM. The correct pharmacological management of angina in HOCM is beta-blockers (reduce heart rate, contractility, and LVOT gradient) or verapamil (non-dihydropyridine CCB that reduces heart rate and improves diastolic filling).

• Option A: Option A is incorrect: nitrates do not sensitize the myocardium to calcium through cGMP; cGMP mediates smooth muscle relaxation in vascular tissue, not calcium channel upregulation in cardiomyocytes; the mechanism described is pharmacologically incorrect.
• Option B: Option B is incorrect: reflex tachycardia is a real adverse effect of nitrates and does worsen HOCM (shortened diastolic filling worsens obstruction), but this is not the primary mechanism of the absolute contraindication; the preload reduction and consequent LV volume reduction is the primary mechanism.
• Option D: Option D is incorrect: coronary steal in the hypertrophied septum is not an established mechanism of nitrate contraindication in HOCM; the contraindication is based on the hemodynamic consequence of LV preload reduction.
• Option E: Option E is incorrect: nitrates have no effect on myocardial hypertrophy or wall thickness; the described mechanism is not pharmacologically plausible.

ANSWER: E

Rationale:

The correct answer is E. Pseudotolerance is the neurohormonal component of nitrate tolerance and is mechanistically distinct from the primary mechanism of ALDH2 inactivation. Nitrate-induced vasodilation lowers blood pressure, which is detected by baroreceptors, triggering reflex activation of the sympathetic nervous system (SNS) and the renin-angiotensin-aldosterone system (RAAS). SNS activation causes arterial vasoconstriction and increases in heart rate and myocardial contractility; RAAS activation causes aldosterone-mediated renal sodium and water retention with volume expansion. Both of these neurohumoral responses directly oppose the hemodynamic goals of nitrate therapy: reflex vasoconstriction counteracts venodilation, and volume expansion restores preload that the nitrate was designed to reduce. The term "pseudo" tolerance is used because the nitrate molecule itself has not lost intrinsic potency — the vascular response to NO at the sGC level remains intact — but the systemic neurohumoral counter-regulation negates the net clinical effect. Pseudotolerance is partially reversible by ACE inhibitors (which attenuate angiotensin II-mediated vasoconstriction and aldosterone release) or spironolactone (which blocks aldosterone-mediated sodium retention at the mineralocorticoid receptor).

• Option A: Option A is incorrect: patient non-adherence to eccentric dosing is a clinical management problem but is not the pharmacological concept of pseudotolerance; pseudotolerance specifically describes a neurohumoral counter-regulatory mechanism.
• Option B: Option B is incorrect: PDE5 upregulation is a proposed molecular adaptation in chronic NO exposure and is not the definition of pseudotolerance; furthermore, adding a PDE5 inhibitor to reverse it is absolutely contraindicated with nitrates.
• Option C: Option C is incorrect: sGC downregulation has been proposed as a molecular tolerance mechanism, but it is not the definition of pseudotolerance; nitrate-free intervals may allow sGC re-expression, but the reversal of this mechanism is not by the drug classes described.
• Option D: Option D is incorrect: cross-tolerance between exogenous nitrates and endogenous eNOS-derived NO is a recognized vascular biology phenomenon but is not the established clinical definition of pseudotolerance; antioxidant supplementation with vitamin C has not demonstrated reliable clinical reversal of nitrate tolerance.

ANSWER: B

Rationale:

The correct answer is B. Isosorbide dinitrate (ISDN) is subject to extensive hepatic first-pass extraction — approximately 75% of an oral dose is metabolized before reaching the systemic circulation, yielding an oral bioavailability of only approximately 25%. First-pass extraction with ISDN is also highly variable between patients due to differences in hepatic blood flow and enzyme expression, making plasma concentrations and clinical effects unpredictable with a fixed oral dose. By contrast, isosorbide mononitrate (ISMN) is the pharmacologically active metabolite of ISDN — it is already in active form and undergoes negligible first-pass hepatic metabolism. ISMN achieves approximately 100% oral bioavailability, meaning the entire administered dose reaches the systemic circulation unchanged. ISMN plasma concentrations are therefore proportional to the dose and far more consistent between patients. This superior pharmacokinetic predictability — not potency, half-life, or safety differences — is the primary pharmacokinetic rationale for ISMN's displacement of ISDN in chronic outpatient stable angina management.

• Option A: Option A is incorrect: ISDN parent compound has a half-life of approximately 1 hour — shorter than ISMN-IR (approximately 5 hours) — but the primary reason for ISDN's replacement is bioavailability unpredictability, not dosing frequency; both agents require eccentric twice-daily dosing for their respective nitrate-free intervals.
• Option C: Option C is incorrect: neither ISDN nor ISMN is administered intravenously for chronic stable angina; IV formulations are used in acute inpatient settings. PVC tubing adsorption is a concern specific to intravenous nitroglycerin (GTN), not the oral dinitrate or mononitrate formulations.
• Option D: Option D is incorrect: ISDN's mononitrate metabolites (2-ISMN and 5-ISMN) are pharmacologically active, not toxic; hepatotoxicity from ISDN metabolite accumulation is not a recognized clinical concern with standard chronic dosing.
• Option E: Option E is incorrect: it is the mononitrate metabolites of ISDN — primarily 5-ISMN — that are pharmacologically active, and renal adjustment for ISDN is not routinely required; ISMN itself is hepatically metabolized to inactive products that are renally excreted, but this does not constitute a safety advantage over ISDN in terms of renal dosing.